Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
GW Pharmaceuticals
British biopharmaceutical company
Nothing else this week.
- FDA
Related events
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.
- The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.
- MMJ International Holdings is pursuing FDA-approved cannabinoid medicines.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.
Coverage
Newest first; wire copies grouped- Insider MonkeyJazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. O